THE CYP3A5 GENOTYPE HAS A MARKED IMPACT ON TACROLIMUS PHARMACOKINETICS BUT DOES NOT AFFECT MIDAZOLAM PHARMACOKINETICS IN A LARGE COHORT OF RENAL TRANSPLANT RECIPIENTS

被引：0
|
作者：
de Jonge, H. [1 ]
de Loor, H. [1 ]
Verbeke, K. [2 ]
Vanrenterghem, Y. [1 ]
Kuypers, D. R. [1 ]
机构：
[1] Katholieke Univ Leuven Hosp, Dept Nephrol & Renal Transplantat, Louvain, Belgium
[2] Katholieke Univ Leuven Hosp, Dept Gastrointestinal Res, Louvain, Belgium
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2011年 / 89卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S5 / S6
页数：2
相关论文
共 50 条
  • [21] Effect of CYP3A5 and MDR1 gene polymorphism on pharmacokinetics of tacrolimus in renal transplant recipients
    Tsuchiya, N
    Satoh, S
    Tada, H
    Li, ZH
    Ohyama, C
    Sato, K
    Suzuki, T
    Kato, T
    Habuchi, T
    JOURNAL OF UROLOGY, 2004, 171 (04): : 490 - 491
  • [22] Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism
    de Jonge, Hylke
    de Loor, Henriette
    Verbeke, Krisitin
    Vanrenterghem, Yves
    Kuypers, Dirk R. J.
    PHARMACOGENOMICS, 2013, 14 (12) : 1467 - 1480
  • [23] Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients
    Zhang, H. J.
    Li, D. Y.
    Zhu, H. J.
    Fang, Y.
    Liu, T. S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2017, 42 (04) : 425 - 432
  • [24] Population Pharmacokinetics of Tacrolimus in Adult Kidney Transplant Patients: Impact of CYP3A5 Genotype on Starting Dose
    Bergmann, Troels K.
    Hennig, Stefanie
    Barraclough, Katherine A.
    Isbel, Nicole M.
    Staatz, Christine E.
    THERAPEUTIC DRUG MONITORING, 2014, 36 (01) : 62 - 70
  • [25] Impact of donor CYP3A5 genotype on pharmacokinetics of tacrolimus in South African paediatric liver transplant patients
    Wheeler, C.
    Masimirembwa, C.
    Mthembu, B.
    Botha, J.
    Scholefield, J.
    Fabian, J.
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2024, 114 (3B): : 70 - 78
  • [26] Impact of CYP3A5 genotype on tacrolimus management in adult heart transplant recipients
    Pasternak, Amy
    Hong, Je-Won
    Lewis, Sarah
    PHARMACOGENETICS AND GENOMICS, 2025, 35 (01): : 35 - 36
  • [27] Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective
    J-L Li
    X-D Wang
    S-Y Chen
    L-S Liu
    Q Fu
    X Chen
    L-C Teng
    C-X Wang
    M Huang
    The Pharmacogenomics Journal, 2011, 11 : 300 - 306
  • [28] Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective
    Li, J-L
    Wang, X-D
    Chen, S-Y
    Liu, L-S
    Fu, Q.
    Chen, X.
    Teng, L-C
    Wang, C-X
    Huang, M.
    PHARMACOGENOMICS JOURNAL, 2011, 11 (04): : 300 - 306
  • [29] Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients
    Roy, Jean Nicholas
    Barama, Azemi
    Poirier, Charles
    Vinet, Bernard
    Roger, Michel
    PHARMACOGENETICS AND GENOMICS, 2006, 16 (09): : 659 - 665
  • [30] Effect of the CYP3A5Genotype of Recipients and Donors on Tacrolimus Pharmacokinetics in Liver Transplant Recipients
    Antonio Buendia, Jefferson
    Otamendi, Esteban
    Cairo, Fernando
    Andres-Ruf
    de Davila, Maria
    Schaiquevich, Paula
    Powazniak, Yanina
    Nafissi, Julieta
    Lazarowski, Alberto
    Bramuglia, Guillermo
    Villamil, Federico
    THERAPEUTIC DRUG MONITORING, 2013, 35 (05) : 658 - 658
12345